De novo missense variants in FBXO11 alter its protein expression and subcellular localization

Anne Gregor1,2,*,†, Tanja Meerbrei1, Thorsten Gerstner3, Annick Toutain4,5, Sally Ann Lynch6, Karen Stals7, Caroline Maxton8, Johannes R. Lemke9, John A. Bernat10, Hannah M. Bombei10, Nicola Foulds11, David Hunt11,12, Alma Kuechler13, Jasmin Beygo13, Petra Stöbe14, Arjan Bouman15, Maria Palomares-Bralo16, Fernando Santos-Simarro16, Sixto García-Minaur16, Marta Pacio-Miguez16, Bernt Popp9, Georgia Vasileiou1, Moritz Hebebrand1, André Reis1, Sarah Schuhmann1, Mandy Krumbiegel1, Natasha J. Brown17,18, Peter Sparber19, Lyusya Melikyan19, Liudmila Bessonova19, Tatiana Cherevatova19, Artem Sharkov20,21, Natalia Shcherbakova20,22, Tabib Dabir23, Usha Kini24, Eva M.C. Schwaibold25, Tobias B. Haack14, Marta Bertoli26, Sabine Hoffjan27, Ruth Falb14, Marwan Shinawi28, Heinrich Sticht29 and Christiane Zweier1,2

1Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany, 2Department of Pediatric, Sørlandet Hospital, Arendal 4838, Norway, 3Department of Human Genetics, Inselspital Bern, University of Bern, Bern 3010, Switzerland, 4Service de Génétique, CHU de Tours, Tours 37044, France, 5UMR 1253, iBrain, Université de Tours, Inserm, Tours 37044, France, 6Department of Clinical Genetics, Temple Street Children’s Hospital Dublin 1, Dublin D01 YC67, Ireland, 7Exeter Genomics Laboratory, Royal Devon & Exeter NHS Foundation Trust, Exeter EX2 5DW, UK, 8Praxis für Kinderneurologie, Hamburg 22767, Germany, 9Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig 04103, Germany, 10Division of Medical Genetics & Genomics, Stead Family Department of Pediatrics, University of Iowa Hospital and Clinics, Iowa City, IA 52242, USA, 11Wessex Clinical Genetics Services, University Hospital Southampton, Southampton SO16 5YA, UK, 12Department of Human Genetics and Genomic Medicine, Faculty of Medicine, University of Southampton, Southampton SO16 5YA, UK, 13Institut für Humangenetik, Universitätssparklinikum Essen, Universität Duisburg-Essen, Essen 45147, Germany, 14Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72076, Germany, 15Department of Clinical Genetics, Erasmus MC University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands, 16Institute of Medical and Molecular Genetics, University Hospital La Paz, Madrid 28046, Spain, 17Department of Paediatrics, University of Melbourne, Royal Children’s Hospital, Melbourne, VIC 3010, Australia, 18Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia, 19Research Centre for Medical Genetics,
Abstract

Recently, others and we identified de novo FBXO11 (F-Box only protein 11) variants as causative for a variable neurodevelopmental disorder (NDD). We now assembled clinical and mutational information on 23 additional individuals. The phenotypic spectrum remains highly variable, with developmental delay and/or intellectual disability as the core feature and behavioral anomalies, hypotonia and various facial dysmorphism as frequent aspects. The mutational spectrum includes intragenic deletions, likely gene disrupting and missense variants distributed across the protein. To further characterize the functional consequences of FBXO11 missense variants, we analyzed their effects on protein expression and localization by overexpression of 17 different mutant constructs in HEK293 and HeLa cells. We found that the majority of missense variants resulted in subcellular mislocalization and/or reduced FBXO11 protein expression levels. For instance, variants localized in the nuclear localization signal and the N-terminal F-Box domain lead to altered subcellular localization with exclusion from the nucleus or the formation of cytoplasmic aggregates and to reduced protein levels in western blot. In contrast, variants localized in the C-terminal Zn-finger UBR domain lead to an accumulation in the cytoplasm without alteration of protein levels. Together with the mutational data, our functional results suggest that most missense variants likely lead to a loss of the original FBXO11 function and thereby highlight haploinsufficiency as the most likely disease mechanism for FBXO11-associated NDDs.

Introduction

Recently, de novo variants in the F-Box protein encoding FBXO11 gene have been described as causative for a variable neurodevelopmental disorder (MIM #618089, intellectual developmental disorder with dysmorphic facies and behavioral anomalies (IDDFBA); (1–3)). Very recently, the first familial case of IDDFBA has also been reported (4). To date, 51 individuals from 49 independent families with pathogenic or likely pathogenic FBXO11 variants have been described (1–6). Affected individuals show variable degrees of cognitive impairment ranging from normal IQ with developmental delay (DD) to severe intellectual disability (ID). Behavioral anomalies are common. Seizures and brain abnormalities are observed in a fraction of individuals (1–4). Growth parameters are highly variable, with short stature and microcephaly being more common than tall stature and macrocephaly. Other frequently reported features include skeletal abnormalities, recurrent infections and vision anomalies. Though facial dysmorphism is observed in the majority of individuals, no recognizable facial gestalt could be delineated (2,3). The mutational spectrum encompasses large multigene and intragenic deletions, likely gene-disrupting (LGD) variants, single amino acid deletions and missense variants. The latter are distributed across the protein and mostly localize to any of the protein domains. No obvious genotype–phenotype correlations could be established (2,3). It has therefore been postulated that haploinsufficiency might be the most likely disease mechanism for all described FBXO11 variants, but gain-of function or dominant negative effects could not be excluded (2,3).

FBXO11 belongs to the F-Box protein family, which contains over 60 members that all carry an F-Box domain in addition to various other protein domains (7,8). FBXO11 contains several functional domains, including the eponymous F-Box domain, which constitutes a subunit of an E3-ubiquitin ligase complex, the SCF complex (SKP1-Cullin-F-Box), which additionally includes SKP1 and subsequently other SCF complex components (9). It also contains three carbohydrate binding/sugar hydrolysis (CASH) domains, which are important for substrate recognition (7,10) and a Zinc-finger UBR (Zf-UBR) domain, which interacts with N-terminal degradation signals in substrate proteins and is a characteristic feature of E3 ubiquitin ligases (11). FBXO11 is a characteristic feature of E3 ubiquitin ligases, the SCF complex (SKP1-Cullin-F-Box), which additionally includes SKP1 and Cullin 1 [CUL1 (7)]. Within the complex, FBXO11 is important for recognition of substrates resulting in their ubiquitination and subsequent degradation. It is also thought to play a role in maintenance of genome stability (12). Its function has mainly been studied in the context of different malignancies such as B-cell lymphoma (10), myelodysplastic syndrome (13), hepatocellular carcinoma (14), gastric cancer (15) and glioblastoma (16). The functional role of FBXO11 in neurodevelopmental disorders (NDDs) and neurodevelopment in general remains elusive.
Germline variants in several other F-Box proteins have also been linked to NDDs inherited either in autosomal recessive (17-22) or in autosomal dominant fashion (23-26). Interestingly, defects in genes involved in protein ubiquitination and proteasomal degradation have recently emerged as a common theme among NDDs [e.g. (27-35)].

We now further delineate the clinical and mutational spectrum of a FBXO11-associated NDD by adding 23 additional cases with de novo FBXO11 variants identified through either chromosomal microarray testing or exome sequencing. Furthermore, we characterize the functional effects of several published and the majority of the novel FBXO11 missense variants. Our results show impaired expression or subcellular localization for the majority of the missense variants, supporting the hypothesis that FBXO11 deficiency is caused by loss of function.

Results

Further delineation of the clinical spectrum

All 23 individuals with FBXO11 aberrations presented with DD and/or ID. Cognitive impairment was variable, ranging from normal IQ with learning difficulties and attention deficits in two individuals to severe ID in three individuals. Developmental milestones were delayed in many cases, with age of walking ranging from 8 months (normal) to no walking ability at age 10 years and age of first words ranging from normal development with bilingual upbringing to no meaningful verbal communication at age 10 years. Behavioral anomalies were commonly observed among individuals and included attention deficits, anxiety and autism. Seizures were reported in nine individuals, and two additional individuals showed abnormal EEG but no seizures. Body measurements were also variable, and in the normal range for the majority of cases, with short stature observed in three individuals. Head circumference was also in the normal range for the majority of cases, with three individuals reported as microcephalic. Increased body weight and/or hyperphagia were reported in four individuals. Non-specific facial dysmorphism were reported in most individuals and/or hyperphagia were reported in four individuals. Non-specific facial dysmorphism were reported in most individuals and/or hyperphagia were reported in four individuals.

Assessment of genotype–phenotype correlations

We considered the group of individuals described here and summarized from previous reports large enough [n=71, 49 independent published cases (1-6) + 22 novel cases] to attempt characterizing genotype–phenotype correlations. For those correlations, we excluded individual 18 who additionally has Koolen–de Vries syndrome (MIM #610443) due to a pathogenic variant in KANSL1, confounding the clinical picture. Summarized clinical data of all cases can be found in Supplementary Material, Table S1. Overweight/hyperphagia were more common in individuals carrying LGD variants compared to carriers of missense variants with a nominally significant P-value [Table 1, chi-square test, 46% versus 18% (P = 0.013)]. When comparing missense variants with only LGD variants predicted to lead to NMD (NMD–LGD), we furthermore found that affected individuals carrying missense variants are significantly more often of short stature compared with NMD-LGD carriers [27% versus 7% (P = 0.046)]. Regarding short stature, carriers of LGDs that are predicted to escape NMD (no-NMD–LGD) are phenotypically more similar to missense variant

Further delineation of the mutational spectrum

In 23 individuals, we identified four deletions, five LGD variants, a single amino acid deletion and 13 missense variants affecting FBXO11 (Fig. 1B). All of these variants were shown to have occurred de novo, and for the majority paternity was confirmed through trio exome analysis. Two deletions affected FBXO11 only partially and deleted exons 1–7 (I21) or 2–11 (I20). Both deletions are predicted to lead to loss of the affected allele through either loss of the start codon of all isoforms (I21), or an out-of-frame deletion of more than a third of the protein including the F-Box domain (I20). The other two deletions affected exons 2–23 of FBXO11 as well as the neighboring gene MSH6 (I22 and I23). LGD variants included three splice variants affecting canonical splice sites. Two of these variants (c.588-2A>G and c.1797+1G>A) are predicted to lead to out-of-frame exclusion of exons 5 and 14, respectively. The third splice variant (c.2338+1G>A) is predicted to lead to the exclusion of exon 19, which is predicted to result in an in-frame deletion of 37 amino acids affecting more than one fourth of the third CASH domain. Lack of patient-derived material precluded further testing of splice variants. The identified nonsense p.Arg742fs*2 and frameshifting p.Ile568Phefs*6 variants are predicted to lead to nonsense-mediated mRNA decay (NMD). All 13 missense variants affected highly conserved amino acid residues (Supplementary Material, Table S1), were absent from public databases such as gnomAD (36), and most were predicted to be damaging by several in-silico prediction programs, but not to affect splicing ([37]; Supplementary Material, Table S2). The missense variants are distributed across the protein and reside in different domains. Variants localized to the putative nuclear localization signal (NLS) as annotated by cnLS mapper ([38]; p.Lys135Arg and p.Arg138Gly), in or around the F-Box domain [p.Arg185His and p.Tyr206Cys], in the CASH domains 1 [p.Gly421Arg], p.(Thr502Pro), p.(Gly549Arg) and p.(Gly550Arg), 2 [p.Thr578Arg], p.(His650Pro) and p.(Asn679Ser)] and 3 [p.Met709Val], or in the C-terminus of the protein [p.Asp910Val]]. The single amino acid deletion affected a highly conserved position in the F-Box domain p.(Phe168del). All observed variants were unique and affected distinct amino acid positions, except for p.Arg138Gly and p.Asp910Val, where a different amino acid exchange has been reported at the same position (2). According to the American College of Medical Genetics and Genomics (ACMG) guidelines (39), all variants identified here are considered likely pathogenic or pathogenic (Supplementary Material, Tables S1 and S3).
| Variant type                  | Novel (%) | Published (%) (1–5) | Total % | Total (%) (P-value versus missense<sup>a</sup>) |
|-----------------------------|-----------|---------------------|---------|-----------------------------------------------|
|                            | All       | All                 | All     | Missense/single aa deletion | LGD all | LGD w NMD | LGD w/o NMD |
| n                           | 22        | 49                  | 71      | n = 34                                        | n = 37  | n = 30    | n = 7       |
| ID/DD                       | 22/22 (100%) | 49/49 (100%)              | 100%   | 34/34 (100%)                                 | 37/37 (100%) | 30/30 (100%) | 7/7 (100%) |
| Mild                        | 23/22 (68%) | 34/49 (47%)               | 54%    | 18/34 (53%)                                  | 20/37 (54%) | 18/30 (60%)  | 2/7 (29%)   |
| Moderate                    | 18/22 (33%) | 18/49 (37%)               | 32%    | 10/34 (29%)                                  | 13/37 (35%) | 10/30 (33%) | 3/7 (42%)   |
| Severe                      | 8/22 (18%)  | 8/49 (16%)                | 14%    | 6/34 (18%)                                   | 4/37 (11%) | 2/30 (7%)   | 2/7 (29%)   |
| Seizures/abnormal EEG       | 10/22 (95%) | 10/49 (21%)               | 29%    | 13/33 (39%)                                  | 7/36 (19%) | 6/30 (20%)  | 1/6 (17%)   |
| Hypotonia                   | 14/20 (70%) | 30/43 (70%)               | 70%    | 22/31 (71%)                                  | 22/32 (69%) | 16/26 (62%)  | 6/6 (100%)  |
| Facial dysmorphism          | 21/22 (95%) | 44/46 (96%)               | 96%    | 30/33 (91%)                                  | 35/35 (100%) | 29/29 (100%) | 6/6 (100%)  |
| Microcephaly                | 3/20 (15%)  | 12/48 (25%)               | 22%    | 4/32 (12%)                                   | 11/36 (31%) | 8/29 (28%)  | 3/7 (43%)   |
| Macrocephaly                | 0/20 (0%)   | 3/48 (6%)                 | 4%     | 2/32 (6%)                                    | 1/36 (3%) | 1/29 (3%)   | 0/7 (0%)     |
| Overweight/hyperphagia      | 4/22 (18%)  | 19/49 (39%)               | 32%    | 6/34 (18%)                                   | 17/37 (46%) (0.013) | 15/30 (50%) (0.006) | 2/7 (29%) (ns) |
| Short stature               | 3/21 (14%)  | 11/48 (23%)               | 20%    | 9/33 (27%)                                   | 5/36 (14%) (ns) | 2/29 (7%) (0.048) | 3/7 (43%) (ns) |
| Tall stature                | 0/20 (0%)   | 4/48 (8%)                 | 6%     | 2/33 (6%)                                    | 2/36 (6%) | 2/29 (7%)   | 0/7 (0%)    |
| Behavioral anomalies        | 12/20 (60%) | 36/48 (75%)               | 71%    | 22/33 (67%)                                  | 26/35 (75%) | 21/28 (75%)  | 5/7 (71%)   |
| Vision impairment           | 10/21 (48%) | 22/45 (49%)               | 48%    | 18/31 (58%)                                  | 14/35 (40%) | 9/29 (31%)  | 5/6 (83%)   |
| Recurrent infections        | 9/19 (47%)  | 9/23 (39%)                | 43%    | 10/20 (50%)                                  | 8/22 (36%) | 6/19 (32%)  | 2/3 (67%)   |
| MRI abnormalities           | 8/19 (42%)  | 14/32 (44%)               | 43%    | 15/29 (52%)                                  | 7/22 (32%) | 6/17 (35%)  | 1/5 (20%)   |

Notes: For individual clinical information see Supplementary Material, Tables S1 and S3, nominally significant P-values are highlighted in bold, all P-values not indicated were not significant; LGD: likely gene-disrupting variants including frameshift mutations, nonsense mutations, splice site variants and intragenic deletions; NMD: nonsense-mediated decay; ns: not significant.

<sup>a</sup>Individual I8 from the current study was excluded from phenotypic summary due to dual diagnosis.

<sup>b</sup>For the familial cases from Lee et al. 2020 only individual 1 was included here.

<sup>c</sup>Significance was calculated using a chi-square test by comparison of number cases with missense variants compared to numbers with different LGD categories (all LGDs, LGD with predicted NMD and LGD without predicted NMD).
Figure 1. Overview of the clinical and mutational spectrum in individuals with FBXO11 aberrations. (A) Clinical images of affected individuals. (B) Schematic drawing of FBXO11 (NM_001190274.1, NP_001177203.1) with annotation of novel [top, blue (missense variants) and purple (LGD variants)] and previously published (bottom, black) aberrations. Domains are color-coded according to InterPro (66). The spectrum encompasses large multi-gene and intragenic deletions, LGD variants, single amino acid deletions and missense variants. Most variants are unique, recurrent variants are underlined. All variants included in the functional assays are marked with the symbol of hash. LGD variants predicted to escape nonsense mediated decay are marked with a black box. Single letter amino acid codes were used due to space constraints.

carriers than to NMD–LGD carriers, and regarding overweight the differences between LGD and missense variant carriers seem to be driven mainly by the NMD–LGD variant carriers. Other clinical features such as the presence of seizures, behavioral anomalies, hypotonia, facial dysmorphism, MRI abnormalities, vision abnormalities or recurrent infections were equally common across groups with different mutation types. One factor that may influence the ability to draw any genotype-phenotype correlations is the presence of additional de novo variants of uncertain significance in other genes that was found in six of
the previously published cases (2,3). It must be noted that none of the observed differences remain statistically significant when correcting for multiple testing. Thus, even larger clinical cohorts will be needed to define potential differences. In summary, while we can observe subtle phenotypic differences between carriers of either missense or LGD variants, no distinct phenotypic groups could be established.

**FBXO11 missense variants are predicted to destabilize the protein**

To further investigate possible effects of missense variants on protein stability and function we first performed in-silico mutational modelling for six novel variants and one previously published variant p.(Tyr506Cys); (3) in domains where structural information is available. The CASH domains of FBXO11 exhibit an elongated structure that consists of right-handed β-helices (40). All variants in this domain have an unfavorable effect on the protein structure either by causing a loss of stabilizing interactions or by inducing steric problems [‘clashes’; (Fig. 2)]. In the Gly421Arg and Gly549Arg variants, tiny glycines (Fig. 2A and C) are replaced by much bulkier arginines, which results in steric clashes (Fig. 2B and D) that potentially destabilize the protein structure. In case of the Tyr506Cys and Asn679Ser variants the wildtype residues form stabilizing hydrophobic (Y506; Fig. 2E) or polar (N679; Fig. 2G) interactions with adjacent residues. In both variants, the wildtype residue is replaced by an amino acid with a shorter sidechain, which could result in a loss of these stabilizing interactions (Fig. 2F and H). In the His650Pro variant, the proline is sterically not tolerated and therefore expected to destabilize the domain structure (not shown). Modelling of the variants located in the F-box domain suggests that they also disturb the domain structure, either by a loss of polar interactions (Arg185His) or by the loss of Phe168 that is central part of the hydrophobic core (Phe168del).

**SCF complex formation is not affected by FBXO11 missense variants**

FBXO11 is part of the SCF ubiquitin ligase complex (7). To test whether any of the missense variants affect formation of the basic SCF complex, we performed co-immunoprecipitation experiments following transient overexpression of Myc-tagged wildtype or mutant FBXO11 for nine of the previously reported and one novel missense variants (see Table 2). All tested missense variants were still able to co-immunoprecipitate CUL1, another subunit of the SCF complex, at similar levels (Supplementary Material, Fig. S2), suggesting that SCF-complex formation is not impaired by the tested missense variants.

**FBXO11 missense variants affect subcellular localization**

FBXO11 localizes to the cytoplasm and the nucleus in HeLa cells (Fig. 3). To investigate whether missense variants might lead to subcellular mislocalization we tested the expression of Myc-tagged FBXO11 constructs each carrying 1 of 17 missense variants either described here or published previously (Table 2; (3) and quantified the observed phenotypes. Missense variants p.(Lys135Arg), p.(Arg138Ser) and p.(Arg138Gly), all located in the putative NLS sequence, abrogated subcellular localization and led to exclusion from the nucleus in all transfected cells (Fig. 3). Furthermore, many of the missense variants located in the F-Box domain [p.(Gln156Arg) and p.(Arg185His)], CASH domains [p.(Tyr506Cys), p.(Ile538Val), p.(Gly549Arg) and p.(Thr623Arg)] and ZF-UBR domain [p.(Ser840Pro) and p.(Asp910Gly)] led to the formation of cytoplasmic aggregates in 50–90% of transfected cells (Fig. 3 and Table 2, quantified in Supplementary Material, Fig. S3A). Similar aggregates were present in only 10% of wildtype cells. To rule out that the observed aggregates are purely an overexpression artifact, we confirmed the presence of the aggregation phenotype for some of the variants also when transfecting lower doses of FBXO11 containing plasmid (200 ng per 12 well versus 400 ng per 12 well), Supplementary Material, Fig. S2B and C). We furthermore also confirmed the formation of cytoplasmic aggregates albeit at a lower frequency of 30–50% of cells for some variants in another cell type, HEK293 cells (Supplementary Material, Fig. S4). To investigate the nature of these aggregates, we picked several of the aggregate forming variants from the different domains [F-Box: p.(Gln156Arg), CASH 1: p.(Gly549Arg) and CASH 2: p.(Thr623Arg)] and performed co-staining with markers for different subcellular organelles, namely the endoplasmic reticulum (ER), the Golgi apparatus, and early or late endosomes/lysosomes. The aggregates did not co-localize with any of the markers, suggesting that they are not associated with any organelle (Supplementary Material, Fig. S5). We next tested whether these aggregates contain other components of the SCF complex by co-staining with antibodies against CUL1 and SKP1. Although most variants tested did not show evidence of co-localization with the SCF complex (Supplementary Material, Fig. S6), we found that aggregates of variant p.(Ser840Pro) partially co-localize with CUL1 in the cytosol, suggesting that some, but not all of those aggregates may be SCF complexes (Supplementary Material, Fig. S6). We finally performed co-staining with an FK2-antibody, which stains ubiquitinated proteins. However, we were also not able to find any evidence of co-localization of aggregates with the FK2 signal (Supplementary Material, Fig. S7), leaving the nature of the observed aggregates unclear for the majority of variants.

**Protein expression is reduced for many FBXO11 missense variants**

We also investigated whether FBXO11 missense variants affect protein expression. We therefore performed western blotting analysis after overexpression of Myc-tagged wildtype or mutant FBXO11. To control for transfection differences we co-transfected a FLAG-tagged control protein (MEF2C), which was used for quantification of blots. We found that missense variants either described here or published previously (Table 2) and quantified the observed phenotypes. Missense variants p.(Lys135Arg), p.(Arg138Ser) and p.(Arg138Gly), all located in the putative NLS sequence, abrogated subcellular localization and led to exclusion from the nucleus in all transfected cells (Fig. 3). Furthermore, many of the missense variants located in the F-Box domain [p.(Gln156Arg) and p.(Arg185His)], CASH domains [p.(Tyr506Cys), p.(Ile538Val), p.(Gly549Arg) and p.(Thr623Arg)] and ZF-UBR domain [p.(Ser840Pro) and p.(Asp910Gly)] led to the formation of cytoplasmic aggregates in 50–90% of transfected cells (Fig. 3 and Table 2, quantified in Supplementary Material, Fig. S3A). Similar aggregates were present in only 10% of wildtype cells. To rule out that the observed aggregates are purely an overexpression artifact, we confirmed the presence of the aggregation phenotype for some of the variants also when transfecting lower doses of FBXO11 containing plasmid (200 ng per 12 well versus 400 ng per 12 well), Supplementary Material, Fig. S2B and C). We furthermore also confirmed the formation of cytoplasmic aggregates albeit at a lower frequency of 30–50% of cells for some variants in another cell type, HEK293 cells (Supplementary Material, Fig. S4). To investigate the nature of these aggregates, we picked several of the aggregate forming variants from the different domains [F-Box: p.(Gln156Arg), CASH 1: p.(Gly549Arg) and CASH 2: p.(Thr623Arg)] and performed co-staining with markers for different subcellular organelles, namely the endoplasmic reticulum (ER), the Golgi apparatus, and early or late endosomes/lysosomes. The aggregates did not co-localize with any of the markers, suggesting that they are not associated with any organelle (Supplementary Material, Fig. S5). We next tested whether these aggregates contain other components of the SCF complex by co-staining with antibodies against CUL1 and SKP1. Although most variants tested did not show evidence of co-localization with the SCF complex (Supplementary Material, Fig. S6), we found that aggregates of variant p.(Ser840Pro) partially co-localize with CUL1 in the cytosol, suggesting that some, but not all of those aggregates may be SCF complexes (Supplementary Material, Fig. S6). We finally performed co-staining with an FK2-antibody, which stains ubiquitinated proteins. However, we were also not able to find any evidence of co-localization of aggregates with the FK2 signal (Supplementary Material, Fig. S7), leaving the nature of the observed aggregates unclear for the majority of variants.

**Integration of functional assay data**

FBXO11 missense variants can lead to a spectrum of functional effects (Fig. 4C), ranging from abnormal localization combined with reduced protein expression for eight variants, abnormal localization with normal protein levels for five variants or...
Figure 2. FBXO11 variants affect stability of the protein. Results of mutational modelling for three novel [p.(Gly421 Arg), p.(Gly549His) and p.(Asn679Ser)] and one previously published missense variants [p.(Tyr506Cys) (3)] are shown. (A) Vicinity of G421 (dark grey) within the \( \beta \)-helix (\( \beta \)-strands are indicated as yellow arrows and key residues are shown in space-filled presentation). (B) The R421 sidechain (dark grey) points towards the interior of the \( \beta \)-helix and forms steric clashes (red arrows) with the sidechains of I400, I415 and H418. (C) Vicinity of G549 within the \( \beta \)-helix. (D) The bulkier R549 sidechain forms steric clashes (red arrows) with the sidechains of H594 and Y598. (E) Y506 forms hydrophobic interactions (green arrows) with H508 and W529. (F) These interactions cannot be formed by the shorter cysteine sidechain in the Y506C variant. (G) N679 forms a sidechain hydrogen bond (green line) to N656. (H) This interaction cannot be formed by the shorter serine sidechain in the N679S variant.

Reduced protein expression with normal localization for three variants. Only one variant did not show any functional defects in the assays tested here [p.(Pro905Arg)]. N-terminal variants localized in the NLS or the F-Box domain all affect localization and stability of FBXO11. C-terminal variants located in the Zf-UBR domain or the very C-terminus are likely to affect localization, but not protein expression levels. For the variants in the CASH domains, no specific pattern could be observed...
with all variants affecting either localization, expression levels or both.

Discussion

With 23 novel cases reported in this study, a total of 74 individuals from 72 independent families with pathogenic or likely pathogenic FBXO11 aberrations according to the ACMG guidelines have been described to date (1–5). The clinical spectrum among all cases remains highly variable with DD and/or ID of varying severity as the only feature present in all individuals. Clinical variability is also reflected by the fact that the first familial cases with a LGD variant in FBXO11 and a mild phenotype have been described recently (4). Most pathogenic variants in FBXO11, however, have occurred de novo. The most frequent additional clinical features include behavioral anomalies, hypotonia, vision impairment and variable non-specific facial dysmorphism alongside with various other anomalies. Recurrent infections and/or otitis media have been reported in several cases, which is notable, however, that seven of the LGD variants are located at the very C-terminus of FBXO11 in immune response. Cleft lip/palate has been reported in five individuals, but does not seem to be a common feature in FBXO11-associated NDDs, though reported in two homozygous Fbxo11 mouse models (41). Of note, the deletions in individuals I22 and I23 as well as three published cases (2,3,6) also included the neighboring MSH6 gene, loss-of-function variants in which are associated NDDs, though reported in two homozygous Fbxo11 mouse models (41). Of note, the deletions in individuals I22 and I23 as well as three published cases (2,3,6) also included the neighboring MSH6 gene, loss-of-function variants in which are associated NDDs, though reported in two homozygous Fbxo11 mouse models (41). Of note, the deletions in individuals I22 and I23 as well as three published cases (2,3,6) also included the neighboring MSH6 gene, loss-of-function variants in which are associated NDDs, though reported in two homozygous Fbxo11 mouse models (41).

Table 2: Overview of functional testing results of FBXO11 missense variants

| Variant | Domain | Modelling | Complex formation | Localization | Expression level 100 | Variant reported |
|---------|--------|-----------|------------------|--------------|----------------------|-----------------|
| K135R(K51R) | NLS | Np | Nd | C | 47 ±14 | 0.03 | This study |
| R138G(R54G) | NLS | Np | Normal | C | 60 ±10 | 0.02 | This study |
| R138S(R54S) | NLS | Np | Normal | C | 53 ±14 | 0.03 | (2) |
| Q156R(Q72R) | F-Box | Np | Normal | Granula | 49 ±13 | 0.03 | (2) |
| F168del(F84del) | F-Box | Loss of stabilizing interaction | Nd | Granula | 69 ±7 | 0.02 | This study |
| R185H(R101H) | F-Box | Loss of stabilizing interaction | Nd | Granula | 55 ±14 | 0.04 | This study |
| Y206C(Y122C) | Np | N | N+C | 43 ±8 | 0.004 | This study |
| G421R(G337R) | CASH | 1 | Steric clashes | Nd | Nd | Nd | Nd | This study |
| TS50P(T418P) | CASH | 1 | Nd | Nd | Nd | Nd | Nd | This study |
| Y506C(Y422C) | CASH | 1 | Loss of stabilizing interaction | Normal | Granula | 59 ±12 | 0.03 | (3) |
| IS84V(B54V) | CASH | 1 | Loss of stabilizing interaction c | Normal | Granula | 98 ±6 | 0.8 | (2) |
| G549R(G465R) | CASH | 1 | Steric clashes | Nd | Granula | 47 ±10 | 0.01 | This study |
| G550R(G466R) | CASH | 1 | Nd | Nd | Nd | Nd | Nd | This study |
| T57S8R(T494R) | CASH | 2 | Nd | Nd | Nd | Nd | Nd | This study |
| T623S(T539R) | CASH | 2 | Electrostatic repulsion c | Normal | Granula | 106 ±12 | 0.7 | (2) |
| H650P(H566P) | CASH | 2 | Destabilization of domain structure | Nd | Nd | Nd | Nd | This study |
| N79S(N595S) | CASH | 2 | Loss of stabilizing interaction | Nd | N+C | 57 ±6 | 0.005 | This study |
| M709V(M625V) | CASH | 3 | Nd | Nd | Nd | Nd | Nd | This study |
| S840P(S756P) | Zf-UBR | Steric clashes c | Normal | Granula, colonic. | 116 ±27 | 0.6 | (2) |

Nd: not determined, Np: not possible, N: nuclear, C: cytoplasmic.

aAnnotation according to the longest isoform NP_001177203.1 (and shorter cloned isoform NP_079409.3).

bDomain structure according to Interpro.

Nd: not determined, Np: not possible, N: nuclear, C: cytoplasmic.

With SCF
Figure 3. FBXO11 variants affect subcellular localization. Schematic drawing of FBXO11 on top left indicates variants with altered subcellular localization in different colors (nuclear exclusion: purple, cytoplasmic aggregates: blue). For immunofluorescence analysis HeLa cells were transiently transfected with 400 ng per 12 well of wildtype or mutant Myc-FBXO11. Cells were fixed 48 h post transfection and stained with an anti-Myc antibody. Images were taken on a Axioimager Z2 with Apotome. Scale bar 20 μM. Arrows point to subcellular aggregates present in several mutants.

more common in individuals carrying LGD variants compared with missense variant carriers. In addition, short stature may be more common in individuals carrying missense variants compared with carriers of LGD variants that are predicted to lead to NMD. Those potential differences, however, are subtle and insufficient to establish distinct phenotypic groups related to particular variants. Therefore, the lack of clear phenotype separation based on different variant types suggests that functional consequences of LGDs and missense variants may be similar and that loss-of function and haploinsufficiency may be the common pathomechanism.

To experimentally validate this hypothesis, we performed several functional assays on 17 different missense variants located in various functional domains. We thereby aimed to assess functional effects and to establish whether differences in these may contribute to the extremely large clinical variability. Of note, these assays can only be considered as additional evidence, but are neither necessary nor sufficient to prove
Figure 4. FBXO11 variants affect protein expression levels. (A) Representative image of western blots used for quantification of FBXO11 expression levels is shown. (B) Quantification of FBXO11 protein levels from western blotting. Value of wildtype FBXO11 was set to 100. Experiments were repeated at least 4 times. Individual values are shown as dots with mean values shown as bars with SEM. P-values were calculated using a one sample t-test with the hypothetical mean set to 100 and a significance threshold of < 0.05 (∗ < 0.05, ∗∗ < 0.01). (C) Schematic overview of different functional consequences observed for tested missense variants with schematic drawing of protein with mutations color-coded according to results of functional assays (red: mislocalization and reduced expression, green: mislocalization, blue: reduced protein expression, black: no functional defect observed).

Pathogenicity of specific variants alone. Based on our data, tested missense variants do not seem to impair interaction with the SCF complex, which is thought to be mediated by the F-Box of FBXO11 [9]. Currently knowledge about amino acids critical for this interaction is lacking. However, we found that the majority of FBXO11 variants resulted in abnormal localization of the protein, either through exclusion from the nucleus or by accumulation in cytoplasmic aggregates. As the FBXO11-containing SCF E3-ubiquitin ligase complex functions primarily in the nucleus [10], the exclusion of FBXO11 from the nucleus is likely to lead
to a loss of an important nuclear function. Consistently, known target proteins of FBXO11 also include various transcriptional targets, for example (10,48). Furthermore, for another F-box protein, FBXW7, subcellular mislocalization and exclusion from the nucleus has been suggested as the key functional impairment for different somatic variants implicated in various cancers (49). On the other hand, abnormal cytoplasmic aggregation of FBXO11 observed for 10 missense variants from the F-Box, CASH 1 and 2 and ZF-UBR domains is also likely to interfere with its original nuclear function. The aggregates could possibly represent overexpression artifacts from abnormal proteins that overwhelm the cellular degradation machinery. It is, however, notable that these aggregates were also present when transfecting lower amounts of plasmid, in another cell type, and were hardly found in cells overexpressing wildtype FBXO11, therefore suggesting that aggregation is related to the specific variants. As the exact function of FBXO11 in neurons is not well understood, the consequences of the observed aggregates are not clear, but an effect through partial mislocalization of FBXO11 in these cytoplasmic aggregates seems plausible. We therefore consider that these missense variants may render FBXO11 more prone to aggregation likely leaving the protein non-functional, which has also been observed in other NDDs (50). For one FBXO11 mutant construct, carrying a variant affecting the ZF-UBR domain, aggregates possibly partially co-localized with components of the SCF complex in the cytoplasm. Whether these complex aggregates represent SCF complexes and whether these complexes may be functional remains elusive and rather unlikely, especially in light of the nuclear role of the SCF complex (10).

In addition, about half of the variants tested showed reduced expression levels, partially overlapping with variants showing abnormal localization. This was true for all variants affecting the NLS and the F-Box domain. Several, but not all of the missense variants in the CASH 1 and 2 domains also led to reduced FBXO11 expression levels. In-silico mutational modelling data predicted destabilizing effects for variants in the CASH domains due to either steric clashes or loss of stabilizing interactions. Our functional data suggest that this destabilization can be reflected by either reduced expression and/or aggregation likely due to misfolding of the CASH domain. Interestingly, somatic FBXO11 missense variants found in various cancer cell lines are mostly affecting CASH domains, are also predicted to lead to a loss of FBXO11 function (10), but are unique from germline variants seen in NDDs. Together with our expression data it therefore seems plausible that these variants with reduced FBXO11 levels result from an unstable protein, which is subsequently degraded. This would suggest that these variants act as hypomorphs and likely lead to a partial loss of FBXO11. However, we cannot rule out the possibility that synthesis of the affected mutant protein is impaired. In general, for missense variants in haploinsufficient genes it has been shown that they are more likely to function through destabilizing protein structure leading to a loss-of-function than to gain-of-function or dominant negative effects (51). Furthermore, pathogenic missense variants are enriched for variants affecting protein stability compared with benign variants (52).

Overall, we found that most FBXO11 missense variants affect either subcellular localization, protein expression levels or both. Only one missense variant [p.(P95SR)] did not show functional effects in our localization and expression assays. Effects of this and other variants on distinct functions such as for example ubiquitination of FBXO11 target proteins were not tested here, but would be interesting to explore in future studies. This does not rule out an effect of this variant on FBXO11 function, and based on the variant location, de novo occurrence and absence in population databases we still consider this variant likely pathogenic. It furthermore highlights the challenges in characterizing various functionally diverse missense variants in one gene, both molecularly and functionally. Such diversity of functional effects of missense variants has already been shown for other NDDs, for example for TCF4 variants causing Pitt-Hopkins syndrome (MIM #610954) or variants in UBE3A causing Angelman syndrome (MIM #105830). For UBE3A, which encodes another nuclear E3 ubiquitin ligase, missense variants have been shown to affect subcellular localization, protein stability and catalytic activity (53). For TCF4, which encodes a transcription factor, missense variants can affect DNA binding, dimerization, transactivation capabilities as well as protein stability and subcellular localization (50). For both disorders, the general disease pathomechanism is haploinsufficiency, and the diverse functional effects are all predicted to abrogate the protein’s original function.

Our data suggest that location of missense variants in the FBXO11 protein influences their functional effects. Variants in the NLS and the F-Box affect localization and expression, variants in the ZF-UBR domain and the C-terminal region tend to affect localization only, whereas the effect of variants in the CASH domains is more variable. Therefore, variant location does not seem to be the sole determining factor, and prediction of functional defects based on variant location alone is likely not possible. In general, the functional diversity is expected to lead to similar downstream loss-of-function effects. For variants with altered localization only, specific gain-of-function effects are not likely, but cannot be excluded. In line with this, levels of ID tend to be more severe in individuals with missense variants affecting subcellular localization only (0 out of 5 with mild DD/ID versus 4 out of 9 for other missense variants tested), but more cases would be necessary to see if this trend holds true. Clinical variability may therefore partially be explained not only by mutation type but also by its specific functional effects although to date numbers are still too small in different mutation subgroups to draw more detailed conclusions.

In summary, we expand the clinical and mutational spectrum of FBXO11-associated NDD and provide evidence that while some clinical variability may be influenced by mutation type and location, most missense variants and LGD variants are likely to function through a shared pathomechanism of loss-of-function and haploinsufficiency.

Materials and Methods

Patients and patient material

Personal communication with colleagues following the initial report (2) and using GeneMatcher (54) and Decipher (55) allowed us to assemble the clinical and mutational data of 23 individuals with FBXO11 variants. Testing in collaborating centers was performed either in the setting of routine diagnostics without the requirement for institutional ethics approval or within research settings approved by the ethical review board of the respective institutions (for details see Supplementary Material, Table S1). Variants were identified through either chromosomal microarray testing (I21 and I23), trio exome sequencing (I2–6, I9, I11–13, I16 and I18–20, I22), single exome (I8, I10 and I14), gene panel analysis (I1 and I17) or exome pool seq (I7). Paternity was confirmed for 15 cases through trio exome sequencing (also see Supplementary Material, Table S1). Informed consent for testing and for publication of mutational and clinical data was obtained.

Patients and patient material

Personal communication with colleagues following the initial report (2) and using GeneMatcher (54) and Decipher (55) allowed us to assemble the clinical and mutational data of 23 individuals with FBXO11 variants. Testing in collaborating centers was performed either in the setting of routine diagnostics without the requirement for institutional ethics approval or within research settings approved by the ethical review board of the respective institutions (for details see Supplementary Material, Table S1). Variants were identified through either chromosomal microarray testing (I21 and I23), trio exome sequencing (I2–6, I9, I11–13, I16 and I18–20, I22), single exome (I8, I10 and I14), gene panel analysis (I1 and I17) or exome pool seq (I7). Paternity was confirmed for 15 cases through trio exome sequencing (also see Supplementary Material, Table S1). Informed consent for testing and for publication of mutational and clinical data was obtained.
from the individuals, their parents or legal guardians. All variants observed in affected individuals are annotated according to NM_001190274.1.

**In-silico analyses**

Missense variants were tested for their potential predicted effects in splicing using SpliceAI (37). Alignments for conservation analysis of missense variants were performed using ClustalW2 (56,57). Identification of FBXO11 NLS was achieved using the online tool cNLS mapper (38). Structural modelling of the CASH domains was performed with HHpred (58) and Modeller (59) based on the crystal structures of the algaline epimerase AlgG [PDB: 4OZZ, 4NK6, (60)]. The F-Box domain was modelled with Swiss-Model (61) based on the crystal structure of FBXL5 [PDB: 6VCD, (62)]. Mutations were modelled with Swiss-Model (61), and the Phe168 deletion was modelled with ModLoop (63). RasMol (64) was used for structure analysis and visualization.

**Plasmids construction**

An expression plasmid containing human FBXO11 (NM_025133.4) and the respective negative control plasmid were obtained from Sino Biologicals, Beijing, China (FBXO11-Myc: HG13948-CM and pCMV-Myc: CV014). Variants from affected individuals are annotated according to the longest FBXO11 isoform (NM_001190274.1). Corresponding variants of both isoforms are indicated in Table 2.

Seventeen missense variants observed in affected individuals in this study or previously published (2) were introduced into the plasmid using a modified version of the Quik-Change site-directed mutagenesis kit (Stratagene, Agilent, Sanat Clara, CA, USA; Table 2). In addition, an expression plasmid containing the MEF2C open reading frame was used as a transfection and normalisation control (MEF2C-FLAG: HG12320-CF, Sino Biologicals, Beijing, China).

**Immunofluorescence**

HeLa cells were grown on coverslips, transiently transfected using jetPrime (Polyplus transfection, Illkirch, France) with either wildtype FBXO11 or one of the mutant constructs and fixated with 4% paraformaldehyde in PBS for 10 min. Immunofluorescence stainings were performed three times. HeLa cells were transfected with 400 ng plasmid per well. To confirm specificity of aggregates a test experiment was performed with 200 ng per well in HeLa cells as well as in HEK293 cells (1.5 μg per well). Cells were scraped into lysis buffer (100 mm TRIS–HCl, pH 8, 150 mm NaCl, 1 mm EDTA and 1% Triton X-100). For western blotting, proteins were separated on stain-free 4–20% SDS-page and western blotting was performed as described previously.

The authors declare no conflicts of interest.

**Funding**

ELAN pilot project from the Center for Interdisciplinary Clinical Research (IZKF) Erlangen (P035 to A.G.); Marie-Sklodowska-Curie individual fellowship from the European Commission (837547 to A.G. and C.Z.); The DDD study presents independent research commissioned by the Health Innovation Challenge Fund. This study makes use of DECIPHER (http://www.deciphergenomics.org), which is funded by Wellcome. See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement. Sequencing and analysis for case I18 was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG).

**Conflict of Interest statement.** The authors declare no conflicts of interest.

**Acknowledgements**

We thank Laila Distel and Christine Suchy for excellent technical assistance. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund. The study makes use of DECIPHER (http://www.deciphergenomics.org), which is funded by Wellcome. See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement. Sequencing and analysis for case I18 was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG).

**Supplementary Material**

Supplementary Material is available at HMG online.
commissioned by the Health Innovation Challenge Fund (HICF-1009-003); Wellcome; National Human Genome Research Institute; National Eye Institute; National Heart, Lung and Blood Institute (grant U01 HG008900); National Human Genome Research Institute (R01 HG009141).

References

1. Fritzten, D., Kuechler, A., Grimmel, M., Becker, J., Peters, S., Sturm, M., Hundertmark, H., Schmidt, A., Kreiss, M., Strom, T.M. et al. (2018) De novo FBXO11 mutations are associated with intellectual disability and behavioural anomalies. Hum. Genet., 137, 401–411.

2. Gregor, A., Sadleir, L.G., Asadollahi, R., Azzarelo-Burri, S., Battaglia, A., Ousager, L.B., Boonsawat, P., Bruel, A.L., Buchert, R., Calpena, E. et al. (2018) De novo variants in the F-box protein FBXO11 in 20 individuals with a variable neurodevelopmental disorder. Am. J. Hum. Genet., 103, 305–316.

3. Jansen, S., van der Werf, I.M., Innes, A.M., Afjenjar, A., Agrawal, P.B., Anderson, I.J., Atwal, P.S., van Binsbergen, E., van den Boogaard, M.J., Castiglia, L. et al. (2019) De novo variants in FBXO11 cause a syndromic form of intellectual disability with behavioral problems and dysmorphisms. Eur. J. Hum. Genet., 27, 738–746.

4. Lee, C.G., Seol, C.A. and Ki, C.S. (2020) The first familial case of inherited intellectual developmental disorder with dysmorphic facies and behavioral abnormalities (IDDFBA) with intellectual disability, delayed motor development and short stature. Hum. Mol. Genet., 29, 972–979.

5. Bonnen, P.E., Yarham, J.W., Besse, A., Wu, P., Faqehi, E.A., Al-Asmari, A.M., Saleh, M.A., Eyaid, W., Hadeel, A., He, L. et al. (2013) Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am. J. Hum. Genet., 93, 471–481.

6. Gai, X., Ghezzi, D., Johnson, M.A., Biagosch, C.A., Shamseldin, T.M., Sturm, M., Hundertmark, H., Schmidt, A., Kreiss, M., Strom, T.M. et al. (2018) De novo variants in the F-box protein FBXO11 are associated with intellectual disability and behavioral problems. Am. J. Hum. Genet., 93, 482–495.

7. Jin, J., Cardozo, T., Lovering, R.C., Eldell, S.J., Pagano, M. and Harper, J.W. (2004) Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev., 18, 2573–2580.

8. Kipreos, E.T. and Pagano, M. (2000) The F-box protein family. Genome Biol., 1, REVIEW3002.

9. Cardozo, T. and Pagano, M. (2004) The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol., 5, 739–751.

10. Duan, S., Cermak, L., Pagan, J.K., Rossi, M., Martinengo, C., di Celle, P.F., Chapuy, B., Shipp, M., Chiarle, R. and Pagano, M. (2012) FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature, 481, 90–93.

11. Munoz-Escobar, J., Kozlov, G. and Gehring, K. (2017) Crystal structure of the UBR-box from UBRE/FBXO11 reveals domain swapping mediated by zinc binding. Protein Sci., 26, 2092–2097.

12. Silverman, J.S., Skaar, J.R. and Pagano, M. (2012) SCF ubiquitin ligases in the maintenance of genome stability. Trends Biochem. Sci., 37, 66–73.

13. Schieber, M., Marinacchio, C., Bolanos, L.C., Haffey, W.D., Greis, K.D., Starczynowski, D.T. and Crispino, J.D. (2020) FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer J., 10, 98.

14. Shao, L., Zhang, X. and Yao, Q. (2020) The F-box protein FBXO11 restrains hepatocellular carcinoma stemness via promotion of ubiquitin-mediated degradation of Snail. FEBS Open Bio, 10, 1810–1820.

15. Abida, W.M., Nikolaev, A., Zhao, W., Zhang, W. and Gu, W. (2007) FBXO11 promotes the neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem., 282, 1797–1804.

16. Wen, X., Li, S., Guo, M., Liao, H., Chen, Y., Kuang, X., Liao, X., Ma, L. and Li, Q. (2020) miR-181a-5p inhibits the proliferation and invasion of drug-resistant glioblastoma cells by targeting F-box protein 11 expression. Oncol. Lett., 20, 235.

17. Ansar, M., Paracha, S.A., Serretti, A., Sarwar, M.T., Khan, J., Ranza, E., Falconnet, E., Iwaszkiewicz, J., Shah, S.F., Qaisar, A.A. et al. (2019) Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature. Hum. Mol. Genet., 28, 972–979.

18. Bonnen, P.E., Yarham, J.W., Besse, A., Wu, P., Faqehi, E.A., Al-Asmari, A.M., Saleh, M.A., Eyaid, W., Hadeel, A., He, L. et al. (2013) Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am. J. Hum. Genet., 93, 471–481.

19. Boone, P.M., Paterson, S., Mohsjeri, K., Zhu, W., Genetti, C.A., Tai, D.J.C., Nori, N., Agrawal, P.B., Bacino, C.A., Bi, W. et al. (2020) Biallelic mutation of FBX7 suggests a novel form of Hennekam syndrome. Am. J. Med. Genet. A, 182, 189–194.

20. Gai, X., Ghezzi, D., Johnson, M.A., Biagosch, C.A., Shamseldin, H.E., Haack, T.B., Reyes, A., Taubikawa, M., Sheldon, C.A., Srinivasan, S. et al. (2013) Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. Am. J. Hum. Genet., 93, 482–495.

21. Harripaual, R., Vasi, N., Mikhailov, A., Rafiq, M.A., Mittal, K., Windpassinger, C., Sheikh, T.I., Noor, A., Mahmood, H., Downey, S. et al. (2018) Mapping autosomal recessive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families. Mol. Psychiatry, 23, 973–984.

22. Mir, A., Sritharan, K., Mittal, K., Vasi, N., Araujo, C., Jamil, T., Rafiq, M.A., Anwar, Z., Mikhailov, A., Rauf, S. et al. (2014) truncation of the E3 ubiquitin ligase component FBXO31 causes non-syndromic autosomal recessive intellectual disability in a Pakistani family. Hum. Genet., 133, 975–984.

23. Balak, C., Belnap, N., Ramsey, K., Joss, S., Devriendt, K., Naymik, M., Jepsen, W., Siniard, A.L., Szelinger, S., Parker, M.E. et al. (2018) A novel FBXO28 frameshift mutation in a child with developmental delay, dysmorphic features, and intractable epilepsy: a second gene that may contribute to the 1q41-q42 deletion phenotype. Am. J. Med. Genet. A, 176, 1549–1558.

24. Holt, R.J., Young, R.M., Crespo, B., Ceroni, F., Curry, C.J., Bellachio, E., Bax, D.A., Ciolfi, A., Simon, M., Fagerberg, C.R. et al. (2019) De novo missense variants in FBXW11 cause diverse developmental phenotypes including brain, eye, and digit anomalies. Am. J. Hum. Genet., 105, 640–657.

25. Kaplanis, J., Samocha, K.E., Wiel, L., Zhang, Z., Arvai, K.J., Eberhardt, R.Y., Gallone, G., Lileveld, S.H., Martin, H.C., McRae, J.F. et al. (2020) Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature, 586, 757–762.

26. O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B.P., Levy, R., Ko, A., Lee, C., Smith, J.D. et al. (2012) Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature, 485, 246–250.

27. Basel-Vanagaite, L., Dallapiccola, B., Ramirez-Solis, R., Segref, A., Thiele, H., Edwards, A., Arends, M.J., Miro, X., White,
54. Sobreira, N., Schiettecatte, F., Valle, D. and Hamosh, A. (2015) GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat., 36, 928–930.

55. Firth, H.V., Richards, S.M., Bevan, A.P., Clayton, S., Corpas, M., Rajan, D., Van Vroen, S., Moreau, Y., Pettett, R.M. and Carter, N.P. (2009) DECIPHER: database of chromosomal imbalance and phenotype in humans using Ensembl resources. Am. J. Hum. Genet., 84, 524–533.

56. Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J. and Lopez, R. (2010) A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res., 38, W695–W699.

57. Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Soding, J. et al. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol., 7, 539.

58. Zimmermann, L., Stephens, A., Nam, S.Z., Rau, D., Kubler, J., Lozajic, M., Gabler, F., Soding, J., Lupas, A.N. and Alva, V. (2018) A completely reimplemented MPI bioinformatics toolkit with a new HHpred server at its Core. J. Mol. Biol., 430, 2237–2243.

59. Webb, B. and Sali, A. (2017) Protein structure modeling with MODELLER. Methods Mol. Biol., 1654, 39–54.

60. Wolfram, F., Kitova, E.N., Robinson, H., Walvoort, M.T., Codée, J.D., Klassen, J.S. and Howell, P.L. (2014) Catalytic mechanism and mode of action of the periplasmic alginate epimerase AlgG. J. Biol. Chem., 289, 6066–6019.

61. Guex, N. and Peitsch, M.C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis, 18, 2714–2723.

62. Wang, H., Shi, H., Rajan, M., Canarie, E.R., Hong, S., Simoneschi, D., Pagano, M., Bush, M.F., Stoll, S., Leibold, E.A. et al. (2020) FBXL5 regulates IRP2 stability in iron homeostasis via an oxygen-responsive [2Fe2S] cluster. Mol. Cell, 78, 31–41 e35.

63. Fiser, A. and Sali, A. (2003) ModLoop: automated modeling of loops in protein structures. Bioinformatics, 19, 2500–2501.

64. Sayle, R.A. and Milner-White, E.J. (1995) RASMOL: biomolecular graphics for all. Trends Biochem. Sci., 20, 374.

65. Schneider, C.A., Rasband, W.S. and Eliceiri, K.W. (2012) NIH image to ImageJ: 25 years of image analysis. Nat. Methods, 9, 671–675.

66. Finn, R.D., Attwood, T.K., Babbitt, P.C., Bateman, A., Bork, P., Bridge, A.J., Chang, H.Y., Dosztanyi, Z., El-Gebali, S., Fraser, M. et al. (2017) InterPro in 2017—beyond protein family and domain annotations. Nucl. Acids Res., 45, D190–D199.